Entera Bio Ltd. (ENTX) · Nov 6, 2026 · Earnings

Entera Bio earnings miss as Phase 3 launch stays on track

Miss — EPS -$0.11 vs approximately -$0.065 consensus

Entera Bio’s Q3 earnings missed consensus, but the company says EB613 Phase 3 startup remains on track and funded through 2030.

Entera is a clinical-stage oral-peptide biotech moving its lead osteoporosis drug, EB613, from Phase 2 into a funded registrational Phase 3 program. The FDA has already aligned with a roughly 750-patient Phase 3 design and a 12-month total-hip BMD endpoint, while the July financing was intended to fund the program through an anticipated NDA submission.

The operating story is still on schedule. Management repeated that first-site activation for EB613 is expected in late 2026, which is consistent with the previously disclosed launch plan rather than a new acceleration or delay. 〔0〕

The quarter missed the narrow earnings benchmark, but the miss is low quality. Net loss was $0.11 per share versus a published consensus of approximately $0.065 per share, while the company attributed much of the deterioration to a $7.5 million non-cash fair-value remeasurement of pre-funded warrants. The miss therefore says more about warrant accounting than about clinical execution.

FigureQ3 2026Q3 2025Consensus
EPS (Financial Results)-$0.11-$0.07-$0.065
R&D expense (R&D Expenses)$4.9M$1.6M
Cash and equivalents (Cash and Cash Equivalents)$265.9M

The financing has materially reduced near-term funding risk. Entera says its cash resources should fund the planned EB613 Phase 3 program through topline results and an anticipated NDA submission, with operations supported into 2030. That is important for a company entering an expensive late-stage trial, although it was already largely established by the July $275 million private placement. 〔1〕

The main new spending is consistent with execution, not deterioration. R&D expense rose to $4.9 million from $1.6 million as Phase 3 startup and OPKO collaboration activity began, confirming that Entera is shifting from preparation toward clinical execution.

Bottom line: This is an earnings miss, but the core EB613 launch and funding story remains intact. The filing is mildly negative versus the earnings bar, not a setback to the company’s late-stage clinical plan.

What to watch next

First EB613 Phase 3 site activation, late 2026

Original filing on SEC EDGAR

More Entera Bio Ltd. news

Entera Bio earnings miss as Phase 3 launch stays on track | ENTX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.